News & Views | Published:

Decade in review—IBD

IBD—genes, bacteria and new therapeutic strategies

Nature Reviews Gastroenterology & Hepatology volume 11, pages 652654 (2014) | Download Citation

IBD is known to be associated with an abnormal response to an unbalanced gut microbiota in genetically predisposed individuals. The therapeutic goal now is to control progression of the disease. Given the heterogeneity of IBD, the two universes of basic and clinical science must work in parallel to realize the hope of personalized therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).

  2. 2.

    et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033–2045 (2009).

  3. 3.

    et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456, 259–263 (2008).

  4. 4.

    et al. Paneth cells as a site of origin for intestinal inflammation. Nature 503, 272–276 (2013).

  5. 5.

    , , , & Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229–241 (2004).

  6. 6.

    et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 1371–1375 (2010).

  7. 7.

    et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15, 382–392 (2014).

  8. 8.

    et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).

  9. 9.

    et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699–710 (2013).

  10. 10.

    et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J. Clin. Invest. 121, 4170–4179 (2011).

Download references

Author information

Affiliations

  1. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, 1428 Madison Avenue, NY 10029, USA.

    • Jean-Frederic Colombel

Authors

  1. Search for Jean-Frederic Colombel in:

Competing interests

J.-F.C. has served as consultant, advisory board member or speaker for Abbvie, ABScience, Amgen, Bristol Meyers Squibb, Celltrion, Danone, Ferring, Genentech, Giuliani SPA, Given Imaging, Janssen, Immune Pharmaceuticals, Merck, Millenium Pharmaceuticals, Nutrition Science Partners, Pfizer. Prometheus Laboratories, Protagonist Therapeutics, Receptos, Sanofi, Schering Plough, Second Genome, Takeda, Teva Pharmaceuticals, UCB Pharma, Vertex and Dr August Wolff.

Corresponding author

Correspondence to Jean-Frederic Colombel.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrgastro.2014.170

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing